Deep Neural Networks (DNNs) are widely regarded as the most effective learning tool for dealing with large datasets, and they have been successfully used in thousands of applications in a variety of fields. Based on these large datasets, they are trained to learn the relationships between various variables. The adaptive moment estimation (Adam) algorithm, a highly efficient adaptive optimization algorithm, is widely used as a learning algorithm in various fields for training DNN models. However, it needs to improve its generalization performance, especially when training with large-scale datasets. Therefore, in this paper, we propose HN Adam, a modified version of the Adam Algorithm, to improve its accuracy and convergence speed. The HN_Adam algorithm is modified by automatically adjusting the step size of the parameter updates over the training epochs. This automatic adjustment is based on the norm value of the parameter update formula according to the gradient values obtained during the training epochs. Furthermore, a hybrid mechanism was created by combining the standard Adam algorithm and the AMSGrad algorithm. As a result of these changes, the HN_Adam algorithm, like the stochastic gradient descent (SGD) algorithm, has good generalization performance and achieves fast convergence like other adaptive algorithms. To test the proposed HN_Adam algorithm performance, it is evaluated to train a deep convolutional neural network (CNN) model that classifies images using two different standard datasets: MNIST and CIFAR-10. The algorithm results are compared to the basic Adam algorithm and the SGD algorithm, in addition to other five recent SGD adaptive algorithms. In most comparisons, the HN Adam algorithm outperforms the compared algorithms in terms of accuracy and convergence speed. AdaBelief is the most competitive of the compared algorithms. In terms of testing accuracy and convergence speed (represented by the consumed training time), the HN-Adam algorithm outperforms the AdaBelief algorithm by an improvement of 1.0% and 0.29% for the MNIST dataset, and 0.93% and 1.68% for the CIFAR-10 dataset, respectively.

Corona Virus Disease (COVID-19) has been announced as a pandemic and is spreading rapidly throughout the world. Early detection of COVID-19 may protect many infected people. Unfortunately, COVID-19 can be mistakenly diagnosed as pneumonia or lung cancer, which with fast spread in the chest cells, can lead to patient death. The most commonly used diagnosis methods for these three diseases are chest X-ray and computed tomography (CT) images. In this paper, a multi-classification deep learning model for diagnosing COVID-19, pneumonia, and lung cancer from a combination of chest x-ray and CT images is proposed. This combination has been used because chest X-ray is less powerful in the early stages of the disease, while a CT scan of the chest is useful even before symptoms appear, and CT can precisely detect the abnormal features that are identified in images. In addition, using these two types of images will increase the dataset size, which will increase the classification accuracy. To the best of our knowledge, no other deep learning model choosing between these diseases is found in the literature. In the present work, the performance of four architectures are considered, namely: VGG19-CNN, ResNet152V2, ResNet152V2 + Gated Recurrent Unit (GRU), and ResNet152V2 + Bidirectional GRU (Bi-GRU). A comprehensive evaluation of different deep learning architectures is provided using public digital chest x-ray and CT datasets with four classes (i.e., Normal, COVID-19, Pneumonia, and Lung cancer). From the results of the experiments, it was found that the VGG19 +CNN model outperforms the three other proposed models. The VGG19+CNN model achieved 98.05% accuracy (ACC), 98.05% recall, 98.43% precision, 99.5% specificity (SPC), 99.3% negative predictive value (NPV), 98.24% F1 score, 97.7% Matthew's correlation coefficient (MCC), and 99.66% area under the curve (AUC) based on X-ray and CT images.

Chronic kidney disease (CKD) is one of today’s most serious illnesses. Because this disease usually does not manifest itself until the kidney is severely damaged, early detection saves many people’s lives. Therefore, the contribution of the current paper is proposing three predictive models to predict CKD possible occurrence within 6 or 12 months before disease existence namely; convolutional neural network (CNN), long short-term memory (LSTM) model, and deep ensemble model. The deep ensemble model fuses three base deep learning classifiers (CNN, LSTM, and LSTM-BLSTM) using majority voting technique. To evaluate the performance of the proposed models, several experiments were conducted on two different public datasets. Among the predictive models and the reached results, the deep ensemble model is superior to all the other models, with an accuracy of 0.993 and 0.992 for the 6-month data and 12-month data predictions, respectively.

The wide prevalence of brain tumors in all age groups necessitates having the ability to make an early and accurate identification of the tumor type and thus select the most appropriate treatment plans. The application of convolutional neural networks (CNNs) has helped radiologists to more accurately classify the type of brain tumor from magnetic resonance images (MRIs). The learning of CNN suffers from overfitting if a suboptimal number of MRIs are introduced to the system. Recognized as the current best solution to this problem, the augmentation method allows for the optimization of the learning stage and thus maximizes the overall efficiency. The main objective of this study is to examine the efficacy of a new approach to the classification of brain tumor MRIs through the use of a VGG19 features extractor coupled with one of three types of classifiers. A progressive growing generative adversarial network (PGGAN) augmentation model is used to produce ‘realistic’ MRIs of brain tumors and help overcome the shortage of images needed for deep learning. Results indicated the ability of our framework to classify gliomas, meningiomas, and pituitary tumors more accurately than in previous studies with an accuracy of 98.54%. Other performance metrics were also examined.